By inhibiting MDSC-dependent nitric oxide and arginase-1, PDE5 inhibitors have been shown to increase tumour infiltration by cytotoxic T-cells and improve the anti-tumour efficacy of adoptive T cell therapy in relevant mouse models59. Here, PDE5A is linked to neoplasm.